Characterization and frequency of biofilms in adenotonsillitis: a retrospective study from a tertiary hospital in North-Eastern Nigeria

Background: Adenotonsillitis, a common condition characterized by inflammation of the adenoids and tonsils, is caused by bacterial and fungal pathogens. Biofilm formation has been linked to disease chronicity and antibiotic resistance. However, the role of biofilms in adenotonsillitis remains poorly understood. This study aims to explore biofilms in adenotonsillitis biopsies, focusing on their characterization, frequency, and demographic distribution by determining the expression of polysaccharides in the biofilm matrix using Congo red stain, determining the presence and frequency of bacterial as well as fungal biofilms in adenotonsillar tissue, investigating any potential associations with disease severity, and evaluating the age and sex distribution of patients with adenotonsillitis. Methods: This retrospective study analyzed formalin-fixed paraffin-embedded adenotonsillitis biopsies (n=50) collected from the university of Maiduguri teaching hospital. The expression of polysaccharides in the biofilm matrix was assessed using congo red stain. Bacterial and fungal biofilms were visualized using crystal violet and Gomori methenamine silver (GMS) stains, respectively. Data on patient demographics, diagnoses, and biofilm characteristics were analyzed. Results: Adenoidtonsillitis was the most common diagnosis (82%), predominantly affecting children aged 0-9 years (76%). Gram's reaction was positive in 70% of cases, while Congo red staining indicated polysaccharide expression in 60%. GMS staining revealed fungal elements in 18% of cases. Conclusions: This study sheds light on the characterization and frequency of bacterial and fungal biofilms in adenotonsillitis, emphasizing importance of biofilms in disease development and persistence. Understanding biofilm-associated infections can improve diagnostic and treatment strategies for adenotonsillitis in Nigeria and beyond

Serum Interferon Gamma (IFN-ɣ) Levels and Hematological Indices in Patients with HIV-MTB Co-Infection in North-Eastern Nigeria

Introduction: The dual epidemic of human immunodeficiency virus (HIV) infection and Mycobacterium tuberculosis (MTB) poses significant health challenges, particularly in sub-Saharan Africa. Understanding the immune response and hematological changes in HIV-MTB co-infection is crucial for better management of affected individuals. Objectives: This study aimed to evaluate the serum levels of IFN-ɣ and hematological indices in patients with HIV-MTB co-infection in North-Eastern Nigeria, as well as explore any potential relationships between these factors. Methods: A total of 88 participants were enrolled in the study, including 44 antiretroviral therapy-naive patients with HIV-MTB co-infection (study group) and 44 HIV mono-infected individuals as controls. Data on personal biodata and clinical details were collected using an interviewer-administered questionnaire. Blood samples were obtained from each participant and analyzed for IFN-ɣ levels using ELISA and hematological indices using an automated hematology analyzer. Statistical analysis, including Mann-Whitney U test, independent samples t-test, and Pearson's correlation analysis, was conducted to compare the study and control groups and assess the relationship between IFN-ɣ levels and hematological parameters. Results: Serum IFN-ɣ was insignificantly increased in the study group compared to the control group (p=0.093). The WBC count was also significantly reduced in the study group compared to the control group (p=0.038). The HGB, HCT, MCV and MCH were significantly reduced in the study group compared to the control group (p=0.001, 0.001, 0.002 and 0.001) respectively. Participants with HIV-TB co-infection have insignificantly increased serum IFN-ɣ levels, low total WBC, lymphocyte and monocyte counts compared to those with HIV mono-infection. In conclusion, participants with HIV-TB co-infection have insignificant increased serum IFN-ɣ levels, low total WBC, and lymphocyte and monocyte counts compared to those with HIV mono-infection. There was no correlation of IFN-ɣ with any of the haematological indices

Molecular Detection of Influenza A(H1N1)Pdm09 Virus Among Chronic Kidney Disease Patients: A Peripheral Blood Sample Approach and Assessment of the Associated Risk Factors

Introduction: Chronic kidney disease (CKD) is a progressive loss of functional nephron characterized by various risk factors. Influenza virus has been found to cause rhabdomyolysis, which is toxic to the kidneys and can initiate or worsen CKD. This study aims to investigate the frequency and molecular detection of Influenza A(H1N1)Pdm09 Virus gene among CKD patients attending University of Maiduguri Teaching Hospital, Nigeria.Materials and Methods: Peripheral blood samples were collected from 150 CKD patients. One-step RT-PCR was performed for detection of influenza virus using the Centers for Disease Control and Prevention protocol. Relevant clinical data were collected in standardized questionnaires from each patient, and medical history was obtained from their hospital records.Results: Conventional PCR analysis revealed that 16% of the CKD patients tested positive for Inf A/Pdm H1N1. The virus frequency was found to be higher among patients in CKD stage 5 (end-stage CKD) and lower in CKD stage 3 (moderate CKD). Additionally, female CKD patients and those in the age group of 55-64 years showed a higher susceptibility to Inf A/Pdm H1N1 infection.Discussion: The study provides evidence of the presence of Inf A/Pdm H1N1 in CKD patients, aligning with previous research showing its involvement in kidney disease aggravation. CKD patients often exhibit immune dysregulation, which might facilitate the virus's invasion and persistence. Conclusion: This study provides evidence of an association between Influenza A(H1N1)Pdm09 viraemia and decreased kidney function among CKD patients. The findings highlight the importance of monitoring and preventing influenza infection in CKD patients to prevent further kidney damage

Humoral immunological kinetics of severe acute respiratory syndrome coronavirus 2 infection and diagnostic performance of serological assays for coronavirus disease 2019: an analysis of global reports

As the coronavirus disease 2019 (COVID-19) pandemic continues to rise and second waves are reported in some countries, serological test kits and strips are being considered to scale up an adequate laboratory response. This study provides an update on the kinetics of humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and performance characteristics of serological protocols (lateral flow assay [LFA], chemiluminescence immunoassay [CLIA] and ELISA) used for evaluations of recent and past SARS-CoV-2 infection. A thorough and comprehensive review of suitable and eligible full-text articles was performed on PubMed, Scopus, Web of Science, Wordometer and medRxiv from 10 January to 16 July 2020. These articles were searched using the Medical Subject Headings terms 'COVID-19', 'Serological assay', 'Laboratory Diagnosis', 'Performance characteristics', 'POCT', 'LFA', 'CLIA', 'ELISA' and 'SARS-CoV-2'. Data from original research articles on SARS-CoV-2 antibody detection >= second day postinfection were included in this study. In total, there were 7938 published articles on humoral immune response and laboratory diagnosis of COVID-19. Of these, 74 were included in this study. The detection, peak and decline period of blood anti-SARS-CoV-2 IgM, IgG and total antibodies for point-of-care testing (POCT), ELISA and CLIA vary widely. The most promising of these assays for POCT detected anti-SARS-CoV-2 at day 3 postinfection and peaked on the 15th day; ELISA products detected anti-SARS-CoV-2 IgM and IgG at days 2 and 6 then peaked on the eighth day; and the most promising CLIA product detected anti-SARS-CoV-2 at day 1 and peaked on the 30th day. The most promising LFA, ELISA and CLIA that had the best performance characteristics were those targeting total SARS-CoV-2 antibodies followed by those targeting anti-SARS-CoV-2 IgG then IgM. Essentially, the CLIA-based SARS-CoV-2 tests had the best performance characteristics, followed by ELISA then POCT. Given the varied performance characteristics of all the serological assays, there is a need to continuously improve their detection thresholds, as well as to monitor and re-evaluate their performances to assure their significance and applicability for COVID-19 clinical and epidemiological purposes